社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
yong168
IP属地:未知
+关注
帖子 · 193
帖子 · 193
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
yong168
yong168
·
2021-12-31
[晕]
非常抱歉,此主贴已删除
看
2,347
回复
评论
点赞
1
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-31
[财迷] [鼓掌]
非常抱歉,此主贴已删除
看
2,800
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-31
[开心] [强] [鼓掌]
非常抱歉,此主贴已删除
看
2,074
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[捂脸] [喷血]
传特斯拉等新能源汽车保费涨超50%,车险公司回应:不实
新能源汽车商业保险专属产品正式上线,在车主群体和舆论中引起了轩然大波。
传特斯拉等新能源汽车保费涨超50%,车险公司回应:不实
看
1,692
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[惊讶]
非常抱歉,此主贴已删除
看
1,868
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[强]
非常抱歉,此主贴已删除
看
2,753
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[汗颜]
非常抱歉,此主贴已删除
看
2,441
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[得意]
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinic
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
看
2,001
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[冷漠]
ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today
The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:
ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today
看
1,681
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yong168
yong168
·
2021-12-30
[笑哭]
非常抱歉,此主贴已删除
看
1,695
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
暂无粉丝
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3570966674623757","uuid":"3570966674623757","gmtCreate":1607875794423,"gmtModify":1607875794423,"name":"yong168","pinyin":"yong168","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":8,"tweetSize":193,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692838300,"gmtCreate":1640911567648,"gmtModify":1640911567726,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[晕] ","listText":"[晕] ","text":"[晕]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692838300","repostId":"1157350742","repostType":4,"isVote":1,"tweetType":1,"viewCount":2347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692831399,"gmtCreate":1640911331718,"gmtModify":1640911331797,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[财迷] [鼓掌] ","listText":"[财迷] [鼓掌] ","text":"[财迷] [鼓掌]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692831399","repostId":"2195944694","repostType":2,"isVote":1,"tweetType":1,"viewCount":2800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692808650,"gmtCreate":1640905456517,"gmtModify":1640905456632,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[开心] [强] [鼓掌] ","listText":"[开心] [强] [鼓掌] ","text":"[开心] [强] [鼓掌]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692808650","repostId":"2195494076","repostType":2,"isVote":1,"tweetType":1,"viewCount":2074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692184152,"gmtCreate":1640875937328,"gmtModify":1640875937429,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[捂脸] [喷血] ","listText":"[捂脸] [喷血] ","text":"[捂脸] [喷血]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692184152","repostId":"1176544303","repostType":4,"repost":{"id":"1176544303","kind":"news","pubTimestamp":1640866163,"share":"https://www.laohu8.com/m/news/1176544303?lang=&edition=full","pubTime":"2021-12-30 20:09","market":"us","language":"zh","title":"传特斯拉等新能源汽车保费涨超50%,车险公司回应:不实","url":"https://stock-news.laohu8.com/highlight/detail?id=1176544303","media":"第一财经","summary":"新能源汽车商业保险专属产品正式上线,在车主群体和舆论中引起了轩然大波。","content":"<div>\n<p>作者:魏文 杨倩雯新能源汽车商业保险专属产品正式上线,在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称,12月23日,他的Model Y投保的总费用为8278元而到了12月27日,同一辆车投保总费用就涨到14902元,涨幅高达80%。其中,车损险的涨幅最大,由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者,以其店内交付...</p>\n\n<a href=\"https://www.yicai.com/news/101275252.html\">Web Link</a>\n\n</div>\n","source":"dyvj","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传特斯拉等新能源汽车保费涨超50%,车险公司回应:不实</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传特斯拉等新能源汽车保费涨超50%,车险公司回应:不实\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 20:09 北京时间 <a href=https://www.yicai.com/news/101275252.html><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>作者:魏文 杨倩雯新能源汽车商业保险专属产品正式上线,在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称,12月23日,他的Model Y投保的总费用为8278元而到了12月27日,同一辆车投保总费用就涨到14902元,涨幅高达80%。其中,车损险的涨幅最大,由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者,以其店内交付...</p>\n\n<a href=\"https://www.yicai.com/news/101275252.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1da1808c476bfbe9388a4202f176a117","relate_stocks":{},"source_url":"https://www.yicai.com/news/101275252.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176544303","content_text":"作者:魏文 杨倩雯新能源汽车商业保险专属产品正式上线,在车主群体和舆论中引起了轩然大波。有车主在社交媒体上爆料称,12月23日,他的Model Y投保的总费用为8278元而到了12月27日,同一辆车投保总费用就涨到14902元,涨幅高达80%。其中,车损险的涨幅最大,由此前的5759元涨到12736元。蔚来、小鹏等车企的产品也被爆出保费大幅上升的情况。但一家造车新势力经销商告诉记者,以其店内交付和保险公司沟通的情况来看,在新能源汽车专属保险上线之后,保费的确出现了上涨的情况,但没有网络上公布的那么夸张,他们测算在新能源专属保险上线之后,新车保险差价在500-1000元之间,涨幅在10%左右。以25万元左右的小鹏P7为例,小鹏汽车门店销售告诉记者,原本商业险是5000多元,现在6000元出头,上涨了大概15%-18%,具体要根据车主的交通违章情况,和之前的出险情况挂钩。某车险公司的销售则表示,之前新能源车保费中有10-15%的返利,现在的价格就相当于返利没有了,他12月29日录入的特斯拉MODEL Y价格上浮在10%左右,但同日比亚迪宋PLUS DM-i出现10%左右的下调。12月29日晚间,小鹏汽车发布了《关于新能源车险产品上线对于小鹏品牌车型商业车险的保费变化的说明》,小鹏汽车方面表示,“据28日各保司反馈的全国保费情况,小鹏全线车型平均涨幅2.9%~18.2%不等(不同保司、不同地区、不同车型涨幅略有差异),具体金额请以当地保司的报价为准。”蔚来汽车一位服务运营负责人告诉记者:“我们在看到网传的信息之后,也找我们合作的保险公司去征询了意见,根据各个保险公司的反馈,网图的信息是不准确的,当然他们每家给我们的反馈的绝对数值有高有低,但肯定是没有网传的这么离谱的。”他表示,从蔚来汽车目前的监测来看,保费有涨跌的,有部分车型可能还会比原来的保费更低的,但也有的车型是高了。蔚来目前监测下来是振幅不大的,大概是 10% 以内。12月29日晚间,蔚来召开新能源汽车专属保险沟通会,会上蔚来汽车表示,该公司向用户提供的包含保费及相关服务权益的2021版用户无忧保包,在车险费改之后,服务包价格依旧保持不变。不包含保险费用的保险无忧包,费用则会根据保司定价进行相应的调整。“这(涨价80%)肯定是夸张了,即使真有这个涨幅,也并不代表行业整体情况。”一名大型产险公司车险人士也对第一财经记者表示。据他介绍,新能源专属车险产品和之前相比保费有涨有跌,部分车型确实出现了涨价,但车险定价中需要考虑多种因素,即使是各新能源品牌同车价的保费变化也会有所不同。此前中国保险行业协会近日向财险公司下发的《关于新能源汽车商业保险专属产品基准纯风险保费表测算调整说明》显示,在车损险费率平滑方面,25万元以下车价的新能源汽车,基准保费一律不上浮;25万元以上车价的新能源汽车,基准保费可以上下浮动。而从商车改革后车险的定价规律来看,最终的定价在基准保费之上还将考虑一系列的费率调整系数,例如以前年度的出险次数就以无赔优待系数(NCD系数)的形式与车险最终定价密切相关,之前多次出险会呈现保费上涨,而连续三年未出险则会享受较低的车险保费折扣。另外,不同的新能源车品牌由于工艺技术大相径庭,其理赔成本也会有很大差异。一名车险理赔人士对记者表示,由于没有发动机,因此电池以及大灯、门、保险杠等表面覆盖件的维修成本是决定不同新能源车型的理赔成本的重要因素,一些造车新势力由于其零部件缺乏可替代性,因此其表面覆盖件维修成本较高,而一些传统车企推出的新能源版本其表面覆盖件可能会有通用性或副厂件等,维修成本大大下降;同时,部分新能源车的设计会导致在驾驶习惯方面的改变,往往使得部分司机在刚开始驾驶新能源车的时候比较难以掌控,也会导致赔付率的上升。针对一些过往赔付率较高的车型,险企也会通过自主定价系数来提高保费,以避免大幅承保亏损。因此,不同品牌车型和不同的驾驶表现会产生出截然不同的最终车险保费情况,一辆车的保费变化情况显然很难代表普遍情况。同时,也有险企人士表示,和过去使用传统商业车险条款相比,新能源汽车商业保险专属产品扩大了新能源车型保障范围,新能源车险核心部分的“三电”系统(电池及储能系统、电机及驱动系统、其他控制系统)均纳入承保范围,车辆行驶、停放、充电及作业期间的车损也被纳入承保范围;并新增了三条新能源车特有附加险:附加外部电网故障损失险、附加自用充电桩损失险和附加自用充电桩责任险。而保障范围的不同也使得两个条款下的车险保费可比性下降。究其根本,新能源车的部分车型面临保费上涨主要就是因为险企赔付率过高。申万宏源报告数据显示,目前新能源车险的赔付率平均接近 85%,行业面临较大承保亏损压力。业内人士表示,新能源车作为一个新生事物,其数据积累和承保经验相对燃油车来说还是欠缺的,而随着之后新能源车的技术发展、险企承保数据的积累以及定价和风控的进一步精细化,赔付率也将回归至合理水平。同时,此次新能源车险专属条款括号里的“试行”两字也给今后的变化留下了空间。华安保险表示,随着新能源汽车技术的快速迭代,新能源车险条款也会不断完善,未来条款的修订或将常态化。","news_type":1,"symbols_score_info":{"09868":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692182208,"gmtCreate":1640875594149,"gmtModify":1640875594225,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[惊讶] ","listText":"[惊讶] ","text":"[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692182208","repostId":"2194099433","repostType":2,"isVote":1,"tweetType":1,"viewCount":1868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692181972,"gmtCreate":1640875041851,"gmtModify":1640875065565,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[强] ","listText":"[强] ","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692181972","repostId":"2191000948","repostType":2,"isVote":1,"tweetType":1,"viewCount":2753,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692183759,"gmtCreate":1640875020800,"gmtModify":1640875020936,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[汗颜] ","listText":"[汗颜] ","text":"[汗颜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692183759","repostId":"2194988102","repostType":2,"isVote":1,"tweetType":1,"viewCount":2441,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692183502,"gmtCreate":1640874976480,"gmtModify":1640874976588,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[得意] ","listText":"[得意] ","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692183502","repostId":"1105609028","repostType":2,"repost":{"id":"1105609028","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640586449,"share":"https://www.laohu8.com/m/news/1105609028?lang=&edition=full","pubTime":"2021-12-27 14:27","market":"us","language":"en","title":"The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1105609028","media":"Benzinga","summary":"Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinic","content":"<p>Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.</p>\n<p>The week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. <b>Pfizer, Inc.</b>received authorization for its oral drug Paxlovid on Wednesday, followed by <b>Merck & Co., Inc.'s</b> molnupiravir.</p>\n<p><b>BiondVax Pharmaceuticals Ltd.</b>rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.</p>\n<p><b>Allakos Inc.</b> was among the worst performers of the week after the company's investigational compound flunkedlate-stage studies in inflammation of the digestive tract.</p>\n<p>Here are the key biopharma catalysts for the unfolding week:</p>\n<p><b>PDUFA Dates</b></p>\n<p>The FDA is scheduled to announce its verdict on <b>Xeris Biopharma Holdings, Inc.'s</b> new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.</p>\n<p>Clinical Readouts/Presentations</p>\n<p><b>Year-end Releases</b></p>\n<p><b>Anavex Life Sciences Corp.</b>: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans</p>\n<p><b>Vanda Pharmaceuticals Inc.</b>: results of Phase 3 study off tradipitant in gastroparesis</p>\n<p><b>Second-Half Data Releases</b></p>\n<p><b>Adagene Inc.</b>: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors</p>\n<p><b>Fourth-quarter Releases</b></p>\n<p><b>Corbus Pharmaceuticals Holdings, Inc.</b>: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus</p>\n<p><b>Vir Biotechnology, Inc.</b>: initial VIR-111, its HIV vaccine candidate, immunology data</p>\n<p><b>Avalo Therapeutics, Inc.</b>: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected</p>\n<p><b>December Releases</b></p>\n<p><b>Taysha Gene Therapies, Inc.</b>: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis</p>\n<p><b>2021/Late-2021 Releases</b></p>\n<p><b>BridgeBio Pharma, Inc.</b>: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)</p>\n<p></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-27 14:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.</p>\n<p>The week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. <b>Pfizer, Inc.</b>received authorization for its oral drug Paxlovid on Wednesday, followed by <b>Merck & Co., Inc.'s</b> molnupiravir.</p>\n<p><b>BiondVax Pharmaceuticals Ltd.</b>rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.</p>\n<p><b>Allakos Inc.</b> was among the worst performers of the week after the company's investigational compound flunkedlate-stage studies in inflammation of the digestive tract.</p>\n<p>Here are the key biopharma catalysts for the unfolding week:</p>\n<p><b>PDUFA Dates</b></p>\n<p>The FDA is scheduled to announce its verdict on <b>Xeris Biopharma Holdings, Inc.'s</b> new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.</p>\n<p>Clinical Readouts/Presentations</p>\n<p><b>Year-end Releases</b></p>\n<p><b>Anavex Life Sciences Corp.</b>: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans</p>\n<p><b>Vanda Pharmaceuticals Inc.</b>: results of Phase 3 study off tradipitant in gastroparesis</p>\n<p><b>Second-Half Data Releases</b></p>\n<p><b>Adagene Inc.</b>: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors</p>\n<p><b>Fourth-quarter Releases</b></p>\n<p><b>Corbus Pharmaceuticals Holdings, Inc.</b>: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus</p>\n<p><b>Vir Biotechnology, Inc.</b>: initial VIR-111, its HIV vaccine candidate, immunology data</p>\n<p><b>Avalo Therapeutics, Inc.</b>: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected</p>\n<p><b>December Releases</b></p>\n<p><b>Taysha Gene Therapies, Inc.</b>: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis</p>\n<p><b>2021/Late-2021 Releases</b></p>\n<p><b>BridgeBio Pharma, Inc.</b>: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)</p>\n<p></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105609028","content_text":"Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.\nThe week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. Pfizer, Inc.received authorization for its oral drug Paxlovid on Wednesday, followed by Merck & Co., Inc.'s molnupiravir.\nBiondVax Pharmaceuticals Ltd.rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.\nAllakos Inc. was among the worst performers of the week after the company's investigational compound flunkedlate-stage studies in inflammation of the digestive tract.\nHere are the key biopharma catalysts for the unfolding week:\nPDUFA Dates\nThe FDA is scheduled to announce its verdict on Xeris Biopharma Holdings, Inc.'s new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.\nClinical Readouts/Presentations\nYear-end Releases\nAnavex Life Sciences Corp.: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans\nVanda Pharmaceuticals Inc.: results of Phase 3 study off tradipitant in gastroparesis\nSecond-Half Data Releases\nAdagene Inc.: Results from ongoing dose escalation of ADG126 monotherapy in solid tumors\nFourth-quarter Releases\nCorbus Pharmaceuticals Holdings, Inc.: topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus\nVir Biotechnology, Inc.: initial VIR-111, its HIV vaccine candidate, immunology data\nAvalo Therapeutics, Inc.: opline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected\nDecember Releases\nTaysha Gene Therapies, Inc.: clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in giant axonal neuropathy and preliminary clinical safety data and Hex A enzyme activity in the plasma and cerebral spinal fluid for TSHA-101 in GM2 gangliosidosis\n2021/Late-2021 Releases\nBridgeBio Pharma, Inc.: topline results from Part A of the Phase 3 ATTRibute-CM trial of Acoramidis for transthyretin amyloid cardiomyopathy (late-2021)","news_type":1,"symbols_score_info":{"ADAG":0.9,"AVTX":0.9,"AVXL":0.9,"BBIO":0.9,"CRBP":0.9,"TSHA":0.9,"VIR":0.9,"VNDA":0.9,"XERS":0.9}},"isVote":1,"tweetType":1,"viewCount":2001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692180067,"gmtCreate":1640874588610,"gmtModify":1640874588687,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[冷漠] ","listText":"[冷漠] ","text":"[冷漠]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692180067","repostId":"1114898675","repostType":2,"repost":{"id":"1114898675","kind":"news","pubTimestamp":1640745937,"share":"https://www.laohu8.com/m/news/1114898675?lang=&edition=full","pubTime":"2021-12-29 10:45","market":"us","language":"en","title":"ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1114898675","media":"InvestorPlace","summary":"The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:","content":"<p>The short-squeeze trade doesn’t appear to be over. Indeed, for investors in <b>Insignia Systems</b>(NASDAQ:<b><u>ISIG</u></b>) and ISIG stock, this trade appears to have some serious legs.</p>\n<p>Various micro cap stocks such as Insignia Systems are seeing impressive buying pressure today. Retail investors are smashing the bid on companies with higher-than-average short interest. As it happens, Insignia Systems is currently one of the most shorted stocks in the market. The company’s short interest ratio of 61% is very high, signaling this stock could be a prime candidate for a squeeze.</p>\n<p>Insignia’s business model is also intriguing to aggressive growth investors. This company focuses on providing physical and digital advertising solutions to clientele in the U.S. As the economy continues to recover from this pandemic, there’s a fundamental growth thesis for this company as well.</p>\n<p>That said, today, all eyes are on Insignia’s potential as a short-squeeze play. Let’s dive into some of the chatter that’s driving this company higher today.</p>\n<p>ISIG Stock Surges Amid Another Short-Squeeze Frenzy</p>\n<p>Any time a company sees roughly 10 times the average daily volume of shares traded before the afternoon, investors know something is up. In the case of Insignia, impressive retail-buying momentum appears to be the cause of this rally today.</p>\n<p>A number of social media sites have lit up with mentions of ISIG stock. Among the top sites capturing eyeballs today is <b>Reddit</b>, and the r/Shortsqueeze channel in particular.</p>\n<p>A number of users have posted their due diligence on the fundamentals that may support a squeeze. A low float, relatively low price per share, and high short interest ratio are among the key factors short-squeeze enthusiasts are jumping on today. Indeed, at a high level, Insignia certainly does appear to be an attractive short-squeeze candidate given these factors.</p>\n<p>That said, this stock has been a highly volatile one this month. Shares of ISIG stock opened the month around $5 per share. This stock then soared to more than $35 per share, before deflating toward the $10 level. Today’s rise of more than 60% has brought ISIG stock back near the $20 level.</p>\n<p>Accordingly, where this stock goes from here remains uncertain. Investors betting on a squeeze must also be aware of the downside risks with such a stock. These volatile moves may be around for some time, so sit back and grab your popcorn. This looks like a fun one to watch.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nISIG Stock Alert: The Short-Squeeze Chatter Sending Insignia Systems Soaring Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 10:45 GMT+8 <a href=https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:ISIG) and ISIG stock, this trade appears to have some serious legs.\nVarious micro cap stocks such as...</p>\n\n<a href=\"https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/isig-stock-alert-the-short-squeeze-chatter-sending-insignia-systems-soaring-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114898675","content_text":"The short-squeeze trade doesn’t appear to be over. Indeed, for investors in Insignia Systems(NASDAQ:ISIG) and ISIG stock, this trade appears to have some serious legs.\nVarious micro cap stocks such as Insignia Systems are seeing impressive buying pressure today. Retail investors are smashing the bid on companies with higher-than-average short interest. As it happens, Insignia Systems is currently one of the most shorted stocks in the market. The company’s short interest ratio of 61% is very high, signaling this stock could be a prime candidate for a squeeze.\nInsignia’s business model is also intriguing to aggressive growth investors. This company focuses on providing physical and digital advertising solutions to clientele in the U.S. As the economy continues to recover from this pandemic, there’s a fundamental growth thesis for this company as well.\nThat said, today, all eyes are on Insignia’s potential as a short-squeeze play. Let’s dive into some of the chatter that’s driving this company higher today.\nISIG Stock Surges Amid Another Short-Squeeze Frenzy\nAny time a company sees roughly 10 times the average daily volume of shares traded before the afternoon, investors know something is up. In the case of Insignia, impressive retail-buying momentum appears to be the cause of this rally today.\nA number of social media sites have lit up with mentions of ISIG stock. Among the top sites capturing eyeballs today is Reddit, and the r/Shortsqueeze channel in particular.\nA number of users have posted their due diligence on the fundamentals that may support a squeeze. A low float, relatively low price per share, and high short interest ratio are among the key factors short-squeeze enthusiasts are jumping on today. Indeed, at a high level, Insignia certainly does appear to be an attractive short-squeeze candidate given these factors.\nThat said, this stock has been a highly volatile one this month. Shares of ISIG stock opened the month around $5 per share. This stock then soared to more than $35 per share, before deflating toward the $10 level. Today’s rise of more than 60% has brought ISIG stock back near the $20 level.\nAccordingly, where this stock goes from here remains uncertain. Investors betting on a squeeze must also be aware of the downside risks with such a stock. These volatile moves may be around for some time, so sit back and grab your popcorn. This looks like a fun one to watch.","news_type":1,"symbols_score_info":{"ISIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692910710,"gmtCreate":1640825754426,"gmtModify":1640825754545,"author":{"id":"3570966674623757","authorId":"3570966674623757","name":"yong168","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570966674623757","authorIdStr":"3570966674623757"},"themes":[],"htmlText":"[笑哭] ","listText":"[笑哭] ","text":"[笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692910710","repostId":"1175206227","repostType":2,"isVote":1,"tweetType":1,"viewCount":1695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}